Janus Henderson Investors led a $50m funding round in TRex Bio.

Janus Henderson Investors, an investment management company, led a $50m funding round in TRex Bio, a biotechnology company, with participation from Balyasny Asset Management, Affinity Asset Advisors, Alexandria Venture Investments, Avego BioScience Capital, Delos Capital, Eli Lilly and Company, Johnson & Johnson Innovation – JJDC, Pfizer Ventures, Polaris Partners and SV Health Investors. “We are grateful for the support of this group of leading healthcare investors, who share our conviction in the potential for Treg modulation to transform the treatment of autoimmune and inflammatory diseases. TRB-061 and our other pipeline programs are designed to apply decades of insight into Treg-mediated immune regulation toward a more precise treatment approach to meet significant unmet needs in immune-mediated diseases. This additional capital enables us to execute our clinical plans for TRB-061 while advancing multiple programs toward the clinic,” Johnston Erwin, TRexBio CEO.